Tracer library / [89Zr]DFO-Per-F(ab')2

[89Zr]DFO-Per-F(ab')2

Also written as [Zr-89]Zr-DFO-Per-F(ab')2

Radionuclide: Zr-89 t½ 4704 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: DFO-conjugated F(ab')2 antibody fragment (anti-HER2, derived from Pertuzumab)
Target / mechanism: HER2-targeting via Pertuzumab-derived F(ab')2 fragment PMID 42592442
Clinical application: HER2-positive tumors (preclinical mouse models) PMID 42592442
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	—	~95%	DFO-Per-F(ab')2	42592442 2026 Acta Pharm Sin B a mixture of 200 μL of DFO-Per, DFO-Per-F(ab')2 or DFO-Per-Fab (0.67 nmol) in 0.5 mol/L HEPES and 100 μL of [89Zr]ZrC2O4 (37 MBq) was incubated at 20 °C for 30 min

Need this precursor?We can point you to suppliers for [89Zr]DFO-Per-F(ab')2, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42592442. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42592442: 'DFO-Per, DFO-Per-F(ab')2 and DFO-Per-Fab were purified using a PD-10 desalting column'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Zr-89 is a positron emitter used only for PET imaging. Linked articles: PMID 42592442. Stage set/updated at stage 39 from PMID 42592442: 'Preclinical evaluation of a novel tetrazine probe within a pretargeted delivery system for theranostics in HER2-positive tumor-bearing mice models.'.